Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 3/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.35 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | PYGL | P06737 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15533171 | 1.00 | GHSR (0.40) | GHSRDPP4FAPDPP8DPP9 | |
| SCHEMBL867706 | 1.00 | GHSR (0.40) | GHSRDPP4FAPDPP8DPP9 | |
| SCHEMBL10039187 | 0.94 | GHSR (0.40) | GHSRDPP4FAPDPP8DPP9 | |
| SCHEMBL13374464 | 0.92 | GHSR (0.39) | GHSRDPP4FAPDPP8DPP9 | |
| SCHEMBL16624606 | 0.91 | GHSR (0.39) | GHSRDPP4FAPDPP8DPP9 | |
| SCHEMBL867608 | 0.91 | GHSR (0.45) | GHSROPRD1CYP51A1F2 | |
| SCHEMBL7896416 | 0.91 | GHSR (0.45) | GHSROPRD1CYP51A1F2 | |
| SCHEMBL867607 | 0.91 | GHSR (0.45) | GHSROPRD1CYP51A1F2 | |
| SCHEMBL868529 | 0.89 | CYP51A1 (0.38) | CYP51A1F2RENPYGL | |
| SCHEMBL10039191 | 0.85 | GHSR (0.46) | GHSROPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1100824-B1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK AS (DK) | 2011-03-02 | — | — | EP | claimed |
| US-7576062-B2 | Administering a patient an effective amount of (2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide; treat the medical disorders resulting from a deficiency in growth hormone | NOVO NORDISK A/S (DK) | 2009-08-18 | — | — | US | claimed |
| US-20050233981-A1 | Administering a patient an effective amount of (2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide; treat the medical disorders resulting from a deficiency in growth hormone | HELSINN HEALTHCARE SA (CH) | 2005-10-20 | — | — | US | claimed |
| US-6919315-B1 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2005-07-19 | — | — | US | claimed |
| EP-1100824-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 2001-05-23 | — | — | EP | claimed |
| WO-2000001726-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 2000-01-13 | — | — | WO | claimed |
| EP-2400986-B1 | ENHANCED MIGRAINE TREATMENTS BASED ON GHRELIN MIMETICS | HELSINN HEALTHCARE SA (CH) | 2015-10-14 | — | — | EP | disclosed |
| US-20150099709-A1 | GHRELIN RECEPTOR AGONISTS FOR THE TREATMENT OF ACHLORHYDRIA | RAQUALIA PHARMA INC. (JP) | 2015-04-09 | — | — | US | disclosed |
| EP-2854810-A1 | GHRELIN RECEPTOR AGONISTS FOR THE TREATMENT OF ACHLORHYDRIA | RaQualia Pharma Inc (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-8673947-B2 | Enhanced migraine treatments based on ghrelin mimetics | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2014-03-18 | — | — | US | disclosed |
| WO-2013175805-A1 | GHRELIN RECEPTOR AGONISTS FOR THE TREATMENT OF ACHLORHYDRIA | RAQUALIA PHARMA INC. (JP) | 2013-11-28 | — | — | WO | disclosed |
| US-20130289068-A1 | ENHANCED MIGRAINE TREATMENTS BASED ON GHRELIN MIMETICS | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2013-10-31 | — | — | US | disclosed |
| US-8486976-B2 | Enhanced migraine treatments based on ghrelin mimetics | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20080207640-A1 | Method of treating cell proliferative disorders using growth hormone secretagogues | SAPPHIRE THERAPEUTICS (US) | 2008-08-28 | — | — | US | disclosed |
| US-20070191283-A1 | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | REJUVENON CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20050261201-A1 | Method of reducing C-reactive protein using growth hormone secretagogues | REJUVENON CORPORATION (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050233981-A1 | Administering a patient an effective amount of (2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide; treat the medical disorders resulting from a deficiency in growth hormone | HELSINN HEALTHCARE SA (CH) | 2005-10-20 | — | — | US | disclosed |
| US-6919315-B1 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2005-07-19 | — | — | US | disclosed |
| EP-1100824-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000001726-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261201-A1 | Method of reducing C-reactive protein using growth hormone secretagogues | CETP, FABP7, TGFB1 | GHSR 14/4885DPP4 436/4885FAP 140/4885 |
| US-20150099709-A1 | GHRELIN RECEPTOR AGONISTS FOR THE TREATMENT OF ACHLORHYDRIA | GIPR, GHSR, GLP1R | GHSR 2/4885DPP4 512/4885FAP 2912/4885 |
| US-20130289068-A1 | ENHANCED MIGRAINE TREATMENTS BASED ON GHRELIN MIMETICS | HTR1E, HTR1B, HTR3B | GHSR 15/4885DPP4 591/4885FAP 1532/4885 |
| US-20050233981-A1 | Administering a patient an effective amount of (2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide; treat the medical disorders resulting from a deficiency in growth hormone | GHSR, GHRHR, MC2R | GHSR 1/4885DPP4 2216/4885FAP 3245/4885 |
| US-20080207640-A1 | Method of treating cell proliferative disorders using growth hormone secretagogues | GHSR, GHRHR, SSTR5 | GHSR 1/4885DPP4 586/4885FAP 903/4885 |
| US-20070191283-A1 | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | GHSR, GHRHR, MLNR | GHSR 1/4885DPP4 153/4885FAP 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.